



Press Release

Cipla appoints Naina Lal Kidwai as an Independent Director on its Board

Mumbai, November 7, 2015: Cipla Ltd, a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients, is delighted to announce the appointment of Ms Naina Lal Kidwai as an independent director on its board effective November 6, 2015.

An MBA from Harvard Business School, Ms Kidwai is recognised as an influential player in the banking and financial services industry. Repeatedly ranked in the Fortune global list of Top Women in Business, she has also been on the Wall Street Journal and Financial Times Global List of Women to Watch and was listed by Time Magazine as one of their 15 Global Influentials 2002. She received the Padma Shri Award in 2007 from the Government of India for her contribution to Trade and Industry.

Until recently Ms Naina Lal Kidwai was Executive Director on the Board of Hongkong and Shanghai Banking Corporation Limited (HSBC) and was Chairman of HSBC India. She is non-executive Director on the Board of Nestle SA and member of the Audit Committee and the Chairman's and Corporate Governance Committee for Asset Liability Management. She is also a global advisor Harvard Business School and Chairman of its South Asia Advisory Board.

A past President of FICCI, Ms Kidwai is the Chairperson of the FICCI Water Mission, FICCI Inclusive Governance Council and the India Sanitation Coalition. Her interests in the environment also include being on the Shakthi Sustainable foundation board and a Global Commissioner for the Climate and Economy. Ms Kidwai has edited 2 books "Contemporary Banking in India" and "30 Women CEOs: Their Voices, Their Stories".

Welcoming her appointment as an independent director, Dr Y K Hamied, Non-Executive Chairman, Cipla Limited said: "We are delighted to have Ms Naina Lal Kidwai join the Board of Cipla. We will benefit immensely from her exemplary business leadership and corporate experience as Cipla evolves on its purpose driven mission to improve the lives of patients around the world."

Ends

About Cipla Limited

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Our portfolio includes 1500 plus products across therapeutic categories with one quality standard globally.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla's emphasis on access for patients was recognized globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than one dollar a day and thereby treating many millions of patients since 2001.

Cipla's research and development focuses on developing innovative products and drug delivery systems.

Media Contacts:

Corporate Communications

Charlotte Chunawala

Mobile: +91 7506257377

E Mail: charlotte.chunawala@cipla.com;

Pallavi Golar

Mobile: +91 9833641788

E Mail: pallavi.golar@cipla.com